Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus–Infected Individuals | Zendy

Maddalena Cerrone | Zendy; Xinzhu Wang | Zendy; Megan Neary | Zendy; Christine Weaver | Zendy; Serge Fedele | Zendy; Isaac Day-Weber | Zendy; Andrew Owen | Zendy; Andrew Hill | Zendy; Myra O. McClure | Zendy; Marta Boffito | Zendy

Open Access

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus–Infected Individuals

Author(s) -

Maddalena Cerrone,

Xinzhu Wang,

Megan Neary,

Christine Weaver,

Serge Fedele,

Isaac Day-Weber,

Andrew Owen,

Andrew Hill,

Myra O. McClure,

Marta Boffito

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy491

Subject(s) - efavirenz , medicine , cmax , pharmacokinetics , rifampicin , emtricitabine , isoniazid , area under the curve , pharmacology , viral load , confidence interval , gastroenterology , human immunodeficiency virus (hiv) , virology , tuberculosis , antiretroviral therapy , pathology

The World Health Organization recommends efavirenz 400 mg (EFV400) as first-line antiretroviral therapy, with a disclaimer that no data with anti-tuberculosis (TB) treatment exist. Many people living with human immunodeficiency virus (PLWH) require TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral exposure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research